Last reviewed · How we verify

NCT05384314

A Retrospective Study to Evaluate the Predictability of Abnormal Arterial Blood Gas Measurements Through Novel Observations of Continuous Trends in Electronically Measured Respiratory Rate in a Mixed Cohort of Respiratory Compromised Patients

Status unknown Last updated 20 May 2022
What this trial tests

trial testing RespiraSense in Respiratory Failure in 322 participants. Status unknown.

Timeline
12 July 2021
Primary endpoint
12 October 2022
12 December 2022

Quick facts

Lead sponsorBeaumont Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment322
Start date12 July 2021
Primary completion12 October 2022
Estimated completion12 December 2022
Sites1 location across Ireland

Drugs / interventions tested

Conditions studied

Sponsor

Beaumont Hospital

Who can join

Adults 18 to 99, any sex, with Respiratory Failure or COPD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A retrospective study to evaluate the predictability of abnormal arterial blood gas measurements through novel observations of continuous trends in electronically measured respiratory in a mixed cohort of respiratory compromised patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Respiratory Failure

Currently open trials in the same condition.

Other Beaumont Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05384314.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing